Impacto orçamentário dos adesivos transdérmicos de rivastigmina no sistema público de saúde brasileiro
Tipo de documento
Apresentação
Descrição
Resumo apresentado na The Professional Society for Health Economics and Outcomes Research (ISPOR)
Fonte
ISPOR
Ano de publicação
2008
Referência (Vancouver)
Bueno RLP, Gomes M, Indelli B. Budget impact of transdermal adhesives of rivastigmine in Brazilian Public Health System [Internet]. In: ISPOR 2008; Toronto, Ontario, Canada. Disponível em: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-13th-annual-international-meeting/budget-impact-of-transdermal-adhesives-of-rivastigmine-in-brazilian-public-health-system
Budget Impact of Transdermal Adhesives of Rivastigmine in Brazilian Public Health System
Document type
Presentation
Description
Abstract presented at The Professional Society for Health Economics and Outcomes Research (ISPOR)
Source
ISPOR
Publication year
2008
Reference (Vancouver)
Bueno RLP, Gomes M, Indelli B. Budget impact of transdermal adhesives of rivastigmine in Brazilian Public Health System [Internet]. In: ISPOR 2008; Toronto, Ontario, Canada. Available from: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-13th-annual-international-meeting/budget-impact-of-transdermal-adhesives-of-rivastigmine-in-brazilian-public-health-system
Objetivo: Estimar o impacto orçamentário da troca de cápsulas de Rivastigmina por adesivos transdérmicos de Rivastigmina no Sistema Único de Saúde (SUS) do Brasil. Métodos: Foi desenvolvido um modelo de simulação sob a perspectiva do Sistema Único de Saúde, com horizonte temporal de três anos. Para explorar o impacto orçamentário mínimo e máximo, foram realizados dois cenários. No cenário A, os pacientes mantêm o perfil de dosagem atual usando adesivos transdérmicos. No cenário B, os pacientes são transferidos com sucesso para doses mais altas usando adesivos transdérmicos conforme recomendações de estudos clínicos e do rótulo do medicamento. As formulações de cápsulas analisadas foram: 1,5 mg; 3 mg; 4,5 mg e 6 mg. As formulações transdérmicas avaliadas foram de 5 cm² e 10 cm². A indicação da dose alvo de 10 cm² de adesivos transdérmicos de rivastigmina, com eficácia semelhante às doses mais altas de cápsulas, baseou-se em ensaios clínicos e farmacológicos. Os dados de dispensação de unidades de medicamentos foram coletados do banco de dados de saúde pública, de outubro de 2004 a setembro de 2007. As informações de custo foram coletadas a partir da lista oficial de reembolso. A taxa de mudança de
Notas
O registro foi originalmente publicado em inglês. A versão em português foi traduzida com o apoio de inteligência artificial.
Abstract
Objetive: To estimate the budget impact of switching from Rivastigmine capsules to Rivastigmine Transdermal Adhesives in Brazilian Public Health System. Methods: A simulation model from Public Health System perspective, with a time horizon of three years was developed. In order to explore the minimum and maximum possible budget impact, two scenarios were performed. In the scenario A the patients are kept in the current treatment dosage profile using transdermal adhesive. In scenario B the patients are successfully switched to higher doses using transdermal adhesives as label and clinical studies recommendations. The capsules formulations analyzed were: 1.5 mg; 3 mg; 4.5 mg e 6 mg. The transdermal formulations evaluated were 5 cm² and 10 cm². The indication of target dose of 10 cm² rivastigmine transdermal adhesives provides efficacy similar to the highest doses of capsules was based on clinical and pharmacological trials. Data from medication unit's dispensation were collected from public health database, ranging from October 2004 to September 2007. Cost information was collected from official reimbursement list. The rate of switching from capsules to transdermal adhesives was based on randomized controlled trial related to caregiver preference. Results were converted in US Dollars (R$ 1,8/USD 1.00). A one-way sensitivity analysis was performed. Results: In scenario A it was estimated that the government could obtain a reduction of USD$2.7 million, or 6.02% of expenses. A reduction of 37% of pharmacy dispensation activities was associated with lowest health service resource utilization. On the other hand in scenario B government expenses are 6.36% higher (USD$3.2 million) but with reduction of 31% of pharmacy dispensation activities. All scenarios are sensible to transdermal adhesives costs. Conclusion: Rivastigmine transdermal adhesives would be advantageous to Brazilian Public Health System providing budget savings with lower resource utilization. Although higher dosage of medication increases expenses, pharmacy dispensation activities would be lower.
Notes
The record was originally published in English. The Portuguese version was translated with the aid of artificial intelligence.
